Foundayo vs Wegovy Pill

Until now, the most effective GLP-1 weight-loss medications came with a catch. They had to be injected.

That is now changing. Wegovy pill (oral semaglutide) and Foundayo (orforglipron) are the first GLP-1 treatments available in a pill form. This will come as great news for patients who have wanted to try GLP-1 treatments but were needle averse.

Wegovy Pill has been approved and licensed in the UK since June 2026. Foundayo is due to be licensed in the UK towards the end of 2026.

This guide aims to compare the two oral GLP-1 weight loss options. It helps explain how Foundayo and Wegovy Pill differ, what the trial evidence actually shows, and which might fit different people better.

In their respective phase 3 trials, Wegovy pill produced a slightly larger average weight loss (around 13.6% over 64 weeks) than Foundayo (between 11.2% & 12.4% over 72 weeks at the highest tested dose). But headline percentages only tell part of the story, because the two tablets are taken in very different ways, and in everyday life, how easy a medicine is to take often matters as much as its trial numbers.

Comparing Foundayo with Wegovy

At a glance

What the two tablets actually are

Wegovy pill is a once-daily tablet of semaglutide. It contains the same active ingredient as the Wegovy injection and as Rybelsus (the lower-dose oral semaglutide licensed for type 2 diabetes), but at a higher strength approved specifically for weight management.

Foundayo is the brand name for orforglipron, also a once-daily tablet, from Eli Lilly. It is a newer kind of molecule rather than a reformulated version of its popular Mounjaro injection.

What unites them is their mechanism. Both imitate GLP-1, a hormone the gut releases after eating. GLP-1 tells the brain you’ve had enough, slows how quickly the stomach empties, and dials down the persistent preoccupation with food that many people on these drugs describe disappearing. Where the two part ways is in their chemistry — and that chemistry is the reason their dosing instructions look so different.

Why one needs an empty stomach and the other doesn’t

Semaglutide is a peptide. This is a short chain of amino acids. Left to itself, stomach acid would tear it apart long before it could reach the bloodstream, which is exactly why semaglutide began life as an injection that bypasses the gut entirely.

To get it into a swallowable tablet, Novo Nordisk pairs the drug with an absorption helper called SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate). SNAC briefly buffers the acidic environment right around the dissolving tablet, giving the semaglutide a narrow window to slip across the stomach wall intact. The trade-off is that this only works under tightly controlled conditions: an empty stomach, no more than a small sip of plain water, and nothing else taken alongside it. Food, other drinks, and even other tablets blunt how much drug gets absorbed.

Orforglipron sidesteps the problem altogether. It is a small synthetic molecule, not a peptide, so stomach acid doesn’t degrade it. With nothing to protect, there’s no need for an absorption enhancer and no fasting window, hence its far more relaxed instructions.

The neat way to remember it is that Wegovy pill is a fragile peptide engineered to survive the stomach for long enough to be absorbed, whereas Foundayo is a sturdy non-peptide the stomach can’t damage in the first place.

What the weight-loss evidence shows

Each tablet was studied in its own large phase 3 programme. Crucially, no trial has pitted them head to head, so any comparison stitches together two studies with somewhat different lengths and participant groups. Treat the gap between them as indicative rather than precise.

The Wegovy pill (OASIS 4 trial) enrolled 307 adults living with obesity, or with excess weight plus a weight-related condition, and without type 2 diabetes. Over 64 weeks alongside lifestyle support, those on 25 mg oral semaglutide lost about 13.6% of their body weight, versus roughly 2.2% on placebo. More than three-quarters dropped at least 5% of their weight, and around 30% lost 20% or more. Among people who stayed the full course, average loss reached about 16.6%.

Foundayo (ATTAIN-1 trial) was far larger, with 3,127 adults in the same broad population. Participants took 6 mg, 12 mg, 36 mg, or placebo for 72 weeks. At the top 36 mg dose, average weight loss was about 11.2% against 2.1% on placebo. Of that group, 54.6% lost at least 10% of their weight, 36% lost at least 15%, and 18.4% lost 20% or more. Completers averaged around 12.4%.

One technical point worth flagging if you’re reading the label rather than the trial: ATTAIN-1 used a 36 mg capsule, but the marketed Foundayo is a tablet, and its highest 17.2 mg tablet strength delivers an equivalent dose. Reported weight loss at that approved tablet dose (about 11.1%) is essentially the same as the 11.2% seen with the trial capsule.

For context, both tablets sit below the leading injectables. Injectable tirzepatide (Mounjaro) reaches roughly 22.5% at its top dose, and injectable semaglutide (Wegovy) around 15% at 2.4 mg. For people still on injectables, resources such as a step‑by‑step guide on injecting retatrutide can help make self‑injection feel more manageable. So the oral options trade some efficacy for the convenience of avoiding needles.

How the side effects compare

Because both drugs act on the same hormone pathway, their side-effect profiles look broadly alike, and the problems are mostly digestive and tend to track the dose.

In OASIS 4, gastrointestinal effects affected around 74% of those on the Wegovy pill compared with 42% on placebo, led by nausea (roughly 47% vs 19%) and vomiting (about 31% vs 6%), with diarrhoea and constipation also common. Notably, the proportion stopping treatment because of side effects (7%) was barely above placebo (6%) — closer than usual for this class.

In ATTAIN-1, the familiar cluster appeared again: nausea, diarrhoea, constipation, vomiting, indigestion, and abdominal pain, mostly mild to moderate and concentrated during the weeks when the dose was being stepped up. Discontinuation due to side effects ranged from about 5.3% to 10.3% across the orforglipron doses, against 2.7% on placebo.

Two further points are worth knowing:

• Hair loss appears on the Foundayo label, reported in roughly 4–5% of users versus 2% on placebo, and more often in women (about 7%) than men (under 1%). It isn’t unique to this drug. In fact thinning is reported across GLP-1 medicines and is generally a temporary reaction to losing weight quickly rather than a direct drug effect, easing once weight settles; if you’re worried about shedding or considering treatments like finasteride for male pattern hair loss, flag it to your NowPatient weight management clinician so they can look at the whole picture.
• Both carry a boxed warning about thyroid C-cell tumours based on rodent studies. The risk hasn’t been established in people, but neither tablet is recommended for anyone with a personal or family history of medullary thyroid carcinoma or MEN2 (multiple endocrine neoplasia type 2).

The daily-routine difference that may matter most

This is where the two genuinely diverge in practice.

The Wegovy pill demands a small but real ritual. Take it first thing, on an empty stomach, with no more than about 120 ml of plain water, then wait at least half an hour before eating, drinking anything else, or taking other tablets. Get it wrong and absorption, and therefore effectiveness, drops. For people already used to morning medicines, that’s manageable. For shift workers, frequent early travellers, anyone juggling other morning tablets, or those who simply don’t want to delay breakfast and coffee, it’s a daily constraint that can wear thin.

Foundayo carries none of that. Take it whenever suits, with a meal, with coffee, with a full glass of water, alongside other medicines.

UK availability and cost

The Wegovy pill is available in the UK now, having been approved by the MHRA and launched on 11 June 2026 through private providers like NowPatient. Its price is broadly in line with the injectable weight-loss medicines, and some patients may also be eligible for Wegovy coupon, savings card and assistance programmes to reduce out‑of‑pocket costs.

Foundayo is not yet available in the UK. Eli Lilly has submitted it for approval in more than 40 countries, the UK among them, but no MHRA timeline has been confirmed. Given how recent its US approval is, a UK arrival is more realistic in late 2026 or early 2027. UK pricing hasn’t been set; for reference, US self-pay prices without insurance start around $149 a month and rise with dosing to roughly $349 at the top 17.2 mg strength, similar to how people using tirzepatide may look to Mounjaro coupon and patient assistance options to manage ongoing costs.

NHS access for either, once licensed, would hinge on a NICE technology appraisal after MHRA approval. Typically adding several more months before routine NHS prescribing.

Which one might suit you

There’s no universally “better” tablet here; the right choice leans on your treatment priorities.

If a strict morning routine isn’t realistic for you, Foundayo is the more practical option. No fasting, no water limit, no waiting around. For irregular schedules, travel, or anyone already taking morning medications, that flexibility is the standout feature (once it actually arrives in the UK).

If you want the most established & efficacious option available today, the Wegovy pill edges ahead. It produced slightly higher average weight loss in trials, and semaglutide carries years of safety and outcome data across its injectable and oral forms.

If you’re stepping down from an injectable, both tablets can serve as maintenance therapy. In the ATTAIN-MAINTAIN study, people moving from injectable Wegovy to Foundayo regained about 1 kg over 52 weeks, while those switching from injectable Mounjaro regained around 5 kg. That’s roughly 75–80% of lost weight maintained in both groups. No equivalent switching trial has been published for the Wegovy pill, though as the same molecule as injectable Wegovy, that transition is conceptually simpler.

Whichever you take, protect your muscle. Some of any weight lost on these medicines comes from lean tissue rather than fat. Three habits help preserve muscle on either drug: losing weight at a steady rather than crash pace, eating enough protein (roughly 1.2–1.6 g per kg of body weight a day — think a palm-sized portion at each meal), and following a structured exercise plan alongside Wegovy or Mounjaro with resistance exercise a couple of times a week.

Frequently asked questions

Which leads to more weight loss?

In their separate trials, the Wegovy pill averaged about 13.6% over 64 weeks and Foundayo about 11.2% over 72 weeks at the top dose. The Wegovy pill looks modestly more effective, but with no direct comparison, the difference shouldn’t be read too literally.

Which is available in the UK first?

The Wegovy pill, which launched on 11 June 2026. Foundayo is expected around late 2026 or early 2027.

Can I eat normally on Foundayo?

Yes. It can be taken at any time, with or without food, and with no restriction on what you drink.

Why does the Wegovy pill need an empty stomach?

Semaglutide is a peptide that stomach acid would otherwise destroy. Its absorption enhancer (SNAC) only does its job on an empty stomach with a small amount of plain water.

Is the Wegovy pill the same as Rybelsus?

Both are oral semaglutide, but they’re separate products. Rybelsus is licensed for type 2 diabetes at up to 14 mg; the Wegovy pill is a 25 mg dose licensed for weight loss.

Can I switch to Foundayo from injectable Wegovy or Mounjaro?

Any switch between GLP-1 medicines should be planned with your NowPatient weight management clinician. Trial data suggests modest regain on switching (about 1 kg from injectable Wegovy, about 5 kg from injectable Mounjaro over a year).

What side effects should I expect?

Mainly digestive. This could include nausea, vomiting, diarrhoea, constipation. The side effects are usually mild to moderate and worst while the dose is increasing. Foundayo additionally lists hair loss, which is common across the class and generally temporary.

Is there a Mounjaro tablet?

No. Tirzepatide (the drug in Mounjaro) hasn’t been made into a tablet; Eli Lilly’s oral offering is orforglipron (Foundayo), a different molecule.

Can I take other tablets alongside the Wegovy pill?

Not at the same time. You should wait at least 30 minutes after the Wegovy pill before any other oral medicine. Foundayo has no such limitations.

The bottom line

The Wegovy pill is the first oral GLP-1 weight-loss tablet you can actually get in the UK, and it edges Foundayo on average trial weight loss (around 13.6% vs 11.2%). Foundayo’s advantage is everyday simplicity with no fasting, no water cap, no timing rules, which for many people is what makes a daily medicine stick.

If you can keep a strict morning routine and want a proven option now, the Wegovy pill is the one available today; if dosing flexibility is the deciding factor, Foundayo is worth waiting for. And for anyone for whom maximum weight loss is the priority, the injectables Mounjaro and Wegovy still set the pace. Check your eligibility today and connect with one of our specialist weight management clinicians.